Is Egrifta (Tesamorelin) Legal in New York?

What Egrifta (Tesamorelin) Is and What the FDA Approved

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that stimulates pituitary release of endogenous growth hormone. The FDA approved Egrifta on January 20, 2010, under NDA 022505, specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. A second formulation, Egrifta SV (2 mg/vial), received FDA approval in 2019.

Why Approval Matters for Legal Status

FDA approval is the most important legal fact for any drug used in clinical practice. Because tesamorelin holds NDA status, it is not a "research chemical" or an unapproved new drug under 21 U.S.C. § 331. Prescribing, dispensing, and possessing it with a valid prescription is fully lawful under federal law. Patients in New York who obtain tesamorelin through a licensed pharmacy with a valid prescription from a licensed provider face no federal or state criminal exposure.

Approved Dosage Form

The approved dosage form is a lyophilized powder reconstituted for subcutaneous injection at 2 mg once daily. The FDA prescribing information specifies administration into the abdomen, rotating sites.

Federal Legal Framework: How Tesamorelin Is Regulated

The Food, Drug, and Cosmetic Act

Under the Federal Food, Drug, and Cosmetic Act (FDCA), tesamorelin is a prescription drug requiring a valid prescription from a licensed practitioner. Dispensing without a prescription violates 21 U.S.C. § 353(b). The drug is not classified as a controlled substance by the DEA, so Schedule II-V rules, including triplicate prescriptions and quantity limits, do not apply.

Is Tesamorelin on the FDA Bulk Substances List?

This question is central for compounding pharmacies. The FDA maintains a list of bulk drug substances that may be used in compounding under section 503A (traditional compounding pharmacies) and a separate list for 503B outsourcing facilities. Tesamorelin is an FDA-approved drug, and FDA policy under CPG Sec. 460.200 generally disfavors compounding copies of commercially available products. Compounding tesamorelin is not categorically prohibited, but a pharmacist must demonstrate a clinical reason the commercial product does not meet the patient's needs (for example, an allergy to an excipient). The FDA has not placed tesamorelin on the 503B "do not compound" list as of this writing, but the agency's draft and final bulk substance nominee lists should be checked regularly because the list is updated.

503A vs. 503B Compounding

503A covers traditional compounding pharmacies that compound based on individual patient prescriptions. 503B covers outsourcing facilities that can compound larger batches for office use without patient-specific prescriptions. Both pathways are theoretically available for tesamorelin, subject to the commercial-availability analysis above. The USP <797> sterile compounding standards apply to any sterile preparation, and New York State requires licensed compounding pharmacies to comply with USP <797> under 8 NYCRR Part 29.

New York State Legal Framework

New York Does Not Separately Schedule Tesamorelin

New York's controlled substance schedules are codified in New York Public Health Law § 3306. As of 2025, tesamorelin does not appear on any New York State controlled substance schedule. No state-specific permit, triplicate prescription, or electronic monitoring report (beyond the standard I-STOP/PMP requirement for controlled substances) is required to prescribe or dispense tesamorelin in New York. The New York State Department of Health I-STOP program mandates electronic prescribing for controlled substances; tesamorelin prescriptions follow standard e-prescribing norms but are not subject to I-STOP reporting.

New York Medical Practice Act

New York Education Law Article 131 governs the practice of medicine. Physicians licensed in New York may prescribe tesamorelin for its approved indication or off-label, as long as the prescription reflects sound clinical judgment documented in the medical record. The New York State Office of the Professions does not list tesamorelin or GHRH analogues as substances requiring special prescribing authority.

New York State Board of Pharmacy

The New York State Board of Pharmacy, operating under Education Law Article 137, licenses pharmacies and pharmacists. A New York-licensed retail or compounding pharmacy may dispense tesamorelin on receipt of a valid prescription. Compounding pharmacies in New York must additionally hold a New York State Department of Health sterile compounding permit if they produce sterile preparations, which tesamorelin requires.

Telehealth Prescribing in New York

New York Public Health Law § 2999-cc governs telehealth. A prescriber may establish a valid prescriber-patient relationship via synchronous audio-video telemedicine and then issue a tesamorelin prescription. The New York State Department of Health telehealth guidance confirms that prescribing via telehealth is permissible when the prescriber is licensed in New York and the patient is physically located in New York at the time of the encounter. New York did not permanently waive the in-person exam requirement for new controlled-substance prescriptions after the COVID-19 public health emergency ended, but tesamorelin is not a controlled substance, so that restriction is irrelevant here.

Clinical Evidence Supporting Tesamorelin Use

Understanding the evidence base matters for any prescriber evaluating whether tesamorelin is appropriate for a given patient. Regulatory legitimacy rests partly on the clinical foundation.

Key Trials in HIV Lipodystrophy

Two phase III randomized controlled trials, LIPO-010A and LIPO-010B, enrolled a combined 816 HIV-positive adults with central fat accumulation. At 26 weeks, tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 15.2% versus 1.2% placebo (P<0.0001). Trunk-fat reductions were sustained at 52 weeks in patients who continued treatment. Falutz et al. Published the pooled analysis in the New England Journal of Medicine in 2010.

Metabolic and Cardiovascular Markers

A substudy published in JAMA found that tesamorelin-treated patients showed significant reductions in triglycerides and improvements in the VAT-to-subcutaneous-fat ratio, without the adverse glucose effects sometimes seen with exogenous growth hormone. Fasting glucose and HbA1c did not worsen significantly in non-diabetic participants over 26 weeks.

Off-Label Evidence: Non-HIV Populations

Tesamorelin has been studied in non-HIV populations, including adults with abdominal obesity, non-alcoholic fatty liver disease (NAFLD), and age-related GH decline. A 2019 trial published in Clinical Infectious Diseases examined tesamorelin's effect on liver fat in HIV and non-HIV participants and found a 37% relative reduction in hepatic fat fraction versus 4% placebo at 12 months (P<0.001). Off-label prescribing in New York is legal but should be accompanied by documented informed consent and a clear rationale in the chart.

IGF-1 Monitoring Guidance

The Endocrine Society's Clinical Practice Guideline on Growth Hormone Deficiency recommends monitoring IGF-1 levels during GH-axis treatment to avoid supraphysiologic exposure. Although this guideline addresses growth hormone deficiency rather than HIV lipodystrophy specifically, many clinicians apply the same monitoring logic to tesamorelin therapy: obtain a baseline IGF-1 before starting and recheck at 6-8 weeks after initiation.

How to Get a Legal Egrifta Prescription in New York

Step 1: Establish a Qualifying Clinical Indication

The FDA-approved indication is HIV-associated lipodystrophy with excess abdominal fat, confirmed by imaging or waist circumference measurement. Off-label use (such as NAFLD or age-related visceral adiposity in non-HIV patients) requires the prescriber to document clinical reasoning. A baseline DEXA or CT scan to quantify VAT is standard before starting therapy.

Step 2: See a Licensed New York Provider

The provider must hold an active New York medical license and must conduct a visit (in-person or synchronous telemedicine) sufficient to establish a prescriber-patient relationship. That means a history, relevant physical examination findings or documented review of imaging, and a documented treatment plan.

Step 3: Obtain the Prescription from a Licensed Pharmacy

Brand-name Egrifta SV is available through specialty pharmacies. Patients should confirm their pharmacy holds a valid New York State license. If a compounding version is clinically necessary (for example, the patient cannot tolerate a specific excipient in the commercial product), the compounding pharmacy must hold a New York sterile compounding permit and, if operating as a 503B facility, must be registered with the FDA's outsourcing facility database.

Step 4: Insurance and Prior Authorization

Most commercial payers in New York cover Egrifta only for the FDA-approved HIV lipodystrophy indication. Prior authorization is required by most plans. Theratechnologies offers a patient assistance program for eligible patients; prescribers can access it through the manufacturer's hub. Off-label use is generally not covered and patients pay out of pocket.

HealthRX Clinical Decision Pathway for New York Tesamorelin Prescribing

The following four-step framework was developed by the HealthRX medical team to help New York providers minimize legal and regulatory risk when prescribing tesamorelin:

1. Confirm indication. Document HIV status or a clinically supported off-label rationale with supporting labs or imaging in the chart before the first prescription.
2. Verify pharmacy license. Check the New York State Board of Pharmacy license lookup and, for compounded preparations, confirm the sterile compounding permit number.
3. Obtain baseline IGF-1. Record the value before initiation. Recheck at 6-8 weeks. Values persistently above the age-adjusted upper limit of normal warrant dose reduction or temporary discontinuation per the FDA label.
4. Document informed consent. For off-label use, obtain and file written informed consent covering the evidence base, approved vs. Non-approved status of the indication, and known risks (fluid retention, arthralgias, glucose changes, potential IGF-1 elevation).

Safety Profile and Prescriber Obligations in New York

Known Adverse Effects

The FDA prescribing label for Egrifta SV lists the following adverse reactions occurring in more than 5% of patients: injection-site reactions (25.4% tesamorelin vs. 6.5% placebo), arthralgia (13.3% vs. 7.9%), peripheral edema (6.4% vs. 2.0%), and myalgia (6.1% vs. 2.4%). Glucose metabolism requires monitoring: the label states that tesamorelin may cause glucose intolerance, and clinicians should check fasting glucose or HbA1c at baseline and periodically.

Contraindications

Tesamorelin is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis from hypophysectomy or head irradiation, pregnancy, and known hypersensitivity to tesamorelin or mannitol. The prescribing information notes that because tesamorelin stimulates IGF-1, use in patients with a history of non-HIV malignancy requires individual risk-benefit assessment.

New York Prescriber Documentation Standards

New York Education Law § 6810 and NYSED guidance on professional misconduct require that prescriptions be issued only for legitimate medical purposes within the context of a valid provider-patient relationship. Prescribers who issue tesamorelin prescriptions without adequate documentation of clinical need risk professional discipline. Telehealth platforms operating in New York must maintain medical records in compliance with 45 CFR Part 164 (HIPAA) and New York Public Health Law § 18.

Compounded Tesamorelin: Legal Nuances

When Compounding Is Permissible

A compounding pharmacy may prepare tesamorelin only when there is a documented clinical difference between the patient's needs and the commercially available product. The FDA's guidance on compounding of commercially available products states: "FDA does not intend to take action against a pharmacy that compounds a drug that is commercially available if the pharmacy is compounding for a specific patient whose prescriber has determined there is a clinical difference." Prescribers must document that clinical difference in writing.

Risks of Unverified Online Sources

Websites selling tesamorelin as a "research chemical" or "for research use only" without requiring a prescription are operating outside the FDCA. Purchasing tesamorelin from such sources exposes the buyer to products of unknown purity, unknown concentration, and potential contamination. A 2020 FDA warning letter program targeted multiple compounding operations dispensing peptides without valid prescriptions. New York residents who receive tesamorelin from non-licensed sources face potential seizure of the product by federal authorities, though personal-use prosecution is rare.

What "Gray Market" Means Here

The term "gray market" applies more accurately to peptides that are not FDA-approved (for example, BPC-157 or CJC-1295 without DAC). Tesamorelin does not fit that description. Its legal pathway is clear: valid prescription, licensed pharmacy, documented indication. The only gray area is compounded versions sold as a "research peptide" by operations that circumvent the prescription requirement, and those operations are not legal under federal or New York law.

Comparing Tesamorelin to Other Peptides by Legal Status

| Peptide | FDA Approval | DEA Schedule | Compounding Pathway | NY-Specific Rule | |---|---|---|---|---| | Tesamorelin (Egrifta) | Yes (NDA 022505) | None | 503A/503B with clinical justification | Standard Rx rules | | Sermorelin | No (discontinued NDA) | None | 503A permitted (on bulk list) | Standard Rx rules | | CJC-1295 | No | None | Not on 503A/503B list; FDA enforcement discretion uncertain | Standard Rx rules | | Ipamorelin | No | None | Not on 503A/503B list; FDA enforcement discretion uncertain | Standard Rx rules | | Semaglutide | Yes (Ozempic/Wegovy) | None | Compounding recently restricted by FDA after shortage resolution | Standard Rx rules |

Sources: FDA Drug@FDA database, FDA 503A bulk substance list.

Frequently Asked Questions